title: Functional promoter -31G/C variant of Survivin gene predict prostate cancer susceptibility among Chinese: a case control study.
abstract: BACKGROUND
  Abnormal expression of Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5, also called as survivin), a novel member of the inhibitor of apoptosis protein (IAP) family, has implications in many types of cancer and is considered as a new therapeutic target. We suppose that genetic variant rs9904341 in the 5' UTR region of survivin gene may be associated with the development and progression of prostate cancer (PCa) in Chinese population.
  
  
  METHODS
  TaqMan assay method was used to genotype the polymorphism in the hospital-based case-control analysis of 665 patients with PCa and 710 age-matched cancer-free controls. The genetic associations with the occurrence and progression of PCa were calculated by logistic regression.
  
  
  RESULTS
  Our results indicated that compared with GG genotypes, there was a statistically significant increased risk of PCa associated with those with CC genotypes [odds ratios (ORs) = 1.57, 95%confidence intervals (CIs) = 1.17-2.13, P = 0.004]. Moreover, stratification analysis revealed that the association was more pronounced in subgroups of nondrinkers, nonsmokers and those without a family history of cancer (all P < 0.05). In addition, we observed that PSA ≥ 20 was more frequent in patients carrying GC/CC genotypes than in those with a wild type genotype.
  
  
  CONCLUSIONS
  The functional survivin rs9904341 genetic variant may have a substantial influence on the PCa susceptibility and evolution.
authors.affiliation: State Key Laboratory of Reproductive Medicine, Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 300 Guangzhou Road, Nanjing 210029, China. lijie203076@yahoo.com.
authors.forename: Jiawei
authors.initials: J
authors.lastname: Chen
authors.forename: Xinhai
authors.initials: X
authors.lastname: Cui
authors.forename: Hai
authors.initials: H
authors.lastname: Zhou
authors.forename: Chao
authors.initials: C
authors.lastname: Qin
authors.forename: Qiang
authors.initials: Q
authors.lastname: Cao
authors.forename: Xiaobing
authors.initials: X
authors.lastname: Ju
authors.forename: Pu
authors.initials: P
authors.lastname: Li
authors.forename: Hongzhou
authors.initials: H
authors.lastname: Cai
authors.forename: Jian
authors.initials: J
authors.lastname: Zhu
authors.forename: Xiaoxin
authors.initials: X
authors.lastname: Meng
authors.forename: Meilin
authors.initials: M
authors.lastname: Wang
authors.forename: Zhengdong
authors.initials: Z
authors.lastname: Zhang
authors.forename: Pengfei
authors.initials: P
authors.lastname: Shao
authors.forename: Jie
authors.initials: J
authors.lastname: Li
authors.forename: Changjun
authors.initials: C
authors.lastname: Yin
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D044466:Asian People / Q000235:genetics*; D016022:Case-Control Studies; D002681:China; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D012307:Risk Factors; D000077022:Survivin
chemical_list: C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin; D017430:Prostate-Specific Antigen